Andrew K.  Balo net worth and biography

Andrew Balo Biography and Net Worth

Insider of DexCom

Andrew (“Andy”) Balo is Executive Vice President, Regulatory Strategy, Clinical Affairs and Strategic Partnership Development at Dexcom.

Andy assumed the role of Executive Vice President, Regulatory Strategy, Clinical Affairs and Strategic Partnership Development at Dexcom in May 2016. In this role, Andy is responsible for overseeing Dexcom’s clinical trials worldwide and developing global regulatory strategies related to these activities.

Since joining Dexcom in 2002, Mr. Balo has held several executive roles, including Executive Vice President, Clinical, Regulatory and Quality, Senior Vice President of Clinical and Regulatory Affairs and Vice President of Clinical and Regulatory Affairs.

Prior to joining Dexcom, Andy served as Vice President of Regulatory and Clinical Affairs for InnerCool Therapies and Endocardial Solutions. Andy also held several leadership positions at St. Jude Medical including Vice President, Regulatory, Clinical and Technical Services and Corporate Vice President, Quality, Regulatory and Clinical Affairs and was an officer of the company.

Andy received his Bachelor of Science degree in Microbiology and Chemistry from the University of Maryland and completed graduate studies at UCLA and Stanford University.

What is Andrew K. Balo's net worth?

The estimated net worth of Andrew K. Balo is at least $1.22 million as of July 6th, 2021. Mr. Balo owns 16,533 shares of DexCom stock worth more than $1,222,946 as of November 14th. This net worth estimate does not reflect any other assets that Mr. Balo may own. Learn More about Andrew K. Balo's net worth.

How do I contact Andrew K. Balo?

The corporate mailing address for Mr. Balo and other DexCom executives is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. DexCom can also be reached via phone at (858) 200-0200 and via email at [email protected]. Learn More on Andrew K. Balo's contact information.

Has Andrew K. Balo been buying or selling shares of DexCom?

Andrew K. Balo has not been actively trading shares of DexCom during the last quarter. Learn More on Andrew K. Balo's trading history.

Who are DexCom's active insiders?

DexCom's insider roster includes Donald Abbey (EVP), Steven Altman (Director), Nicholas Augustinos (Director), Andrew Balo (Insider), Quentin Blackford (COO), Michael Brown (EVP), Richard Collins (Director), Matthew Dolan (SVP), Richard Doubleday (EVP), Paul Flynn (EVP), Mark Foletta (Director), Bridgette Heller (Director), Barbara Kahn (Director), Jacob Leach (EVP), Jeffrey Moy (EVP), Patrick Murphy (EVP), Steven Pacelli (Insider), Chad Patterson (EVP), Barry Regan (EVP), Kevin Sayer (CEO), Shelly Selvaraj (SVP), Sumi Shrishrimal (SVP), Jay Skyler (Director), Sadie Stern (EVP), and Jereme Sylvain (CAO). Learn More on DexCom's active insiders.

Are insiders buying or selling shares of DexCom?

During the last twelve months, insiders at the medical device company sold shares 29 times. They sold a total of 253,409 shares worth more than $33,229,896.21. The most recent insider tranaction occured on September, 9th when EVP Sadie Stern sold 426 shares worth more than $29,457.90. Insiders at DexCom own 0.3% of the company. Learn More about insider trades at DexCom.

Information on this page was last updated on 9/9/2024.

Andrew K. Balo Insider Trading History at DexCom

See Full Table

Andrew K. Balo Buying and Selling Activity at DexCom

This chart shows Andrew K. Balo's buying and selling at DexCom by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

DexCom Company Overview

DexCom logo
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $74.68
Low: $71.75
High: $75.78

50 Day Range

MA: $69.77
Low: $65.68
High: $74.85

2 Week Range

Now: $74.68
Low: $62.34
High: $142.00

Volume

4,192,267 shs

Average Volume

3,919,698 shs

Market Capitalization

$29.17 billion

P/E Ratio

44.72

Dividend Yield

N/A

Beta

1.17